Featured Research

from universities, journals, and other organizations

MRI catches breast cancer early in at-risk survivors of childhood Hodgkin lymphoma

Date:
May 28, 2014
Source:
University Health Network (UHN)
Summary:
Magnetic-resonance imaging (MRI) detected invasive breast tumors at very early stages, when cure rates are expected to be excellent reports the largest clinical study to evaluate breast cancer screening of female survivors of childhood Hodgkin lymphoma (HL). These patients are at increased risk because they received chest radiation.

The largest clinical study to evaluate breast cancer screening of female survivors of childhood Hodgkin lymphoma (HL), who are at increased risk because they received chest radiation, shows that magnetic-resonance imaging (MRI) detected invasive breast tumours at very early stages, when cure rates are expected to be excellent.

The finding, published online today in the American Cancer Society Journal Cancer, underscores the need for at-risk childhood HL survivors and primary care physicians to be aware of established guidelines that recommend breast MRI screening from the age of 25 years or eight years following chest radiation (whichever is later), says principal investigator Dr. David Hodgson, a radiation oncologist at Princess Margaret Cancer Centre, University Health Network.

"Female survivors of childhood HL who had chest radiation should speak with their family doctor about after-care assessment and breast cancer screening" says Dr. Hodgson. "We estimate that 75% of women who are at high risk because of prior radiotherapy to the chest are not being screened. So my hope is that this new evidence will encourage these survivors to discuss early screening with their doctors.There is a provincial pediatric oncology aftercare system already in place to help them, organized by the Pediatric Oncology Group of Ontario (POGO)."

Dr. Hodgson's study team, in collaboration with colleagues at the Dana Farber Cancer Institute in Boston, performed 274 breast MRI screens on 96 women from 2005 to 2012. Ten breast cancers -- half of them invasive tumors -- were diagnosed in nine women during 363 person-years follow up. The median age of breast cancer diagnosis was 39 years (range 24 to 43 years), and the median latency period between HL diagnosis and age at breast cancer diagnoses was 21 years (range 12 to 27 years). "This illustrates the young age at which these cancers can occur. For some of these women, if they had been screened starting at age 40 or 50 like average risk women, it would have been too late."

Of the 10 detected breast tumours, five were visible on both MRI and mammogram; three were visible only on MRI; and two were detected on mammogram alone (but were non-invasive). The median size of invasive tumors size was 8mm (range 3-15mm) and none had spread to the lymph nodes. These results are substantially better than prior studies using only mammographic screening in these young patients, in which almost half of the cancers detected had cancer spread to lymph nodes. Dr. Hodgson points out that because MRI screening is so much more sensitive to small changes in the appearance of the breast tissue than mammography, up to a third of patients may be called back for further testing of suspicious findings, many of which are benign or not clinically significant and therefore require no treatment. "It's important to forewarn at-risk HL survivors because call backs definitely heighten anxiety."


Story Source:

The above story is based on materials provided by University Health Network (UHN). Note: Materials may be edited for content and length.


Journal Reference:

  1. Minh Thi Tieu, Candemir Cigsar, Sameera Ahmed, Andrea Ng, Lisa Diller, B.-A. Millar, Pavel Crystal, David C. Hodgson. Breast cancer detection among young survivors of pediatric Hodgkin lymphoma with screening magnetic resonance imaging. Cancer, 2014; DOI: 10.1002/cncr.28747

Cite This Page:

University Health Network (UHN). "MRI catches breast cancer early in at-risk survivors of childhood Hodgkin lymphoma." ScienceDaily. ScienceDaily, 28 May 2014. <www.sciencedaily.com/releases/2014/05/140528102927.htm>.
University Health Network (UHN). (2014, May 28). MRI catches breast cancer early in at-risk survivors of childhood Hodgkin lymphoma. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/05/140528102927.htm
University Health Network (UHN). "MRI catches breast cancer early in at-risk survivors of childhood Hodgkin lymphoma." ScienceDaily. www.sciencedaily.com/releases/2014/05/140528102927.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins